Light To Guide Our Feet
Light To Guide Our Feet

Menu

Collapse

Search Result

Collapse

Announcement

Collapse
No announcement yet.

What's Going On

Collapse

There are currently 72 users online. 11 members and 61 guests.

Most users ever online was 3,930 at 06:07 PM on 04-20-2019.

102 results in 0.0108 seconds.
Keywords
Members
Tags
covid-19 x
  •  

  • HHS says Trump Administration Partners with CVS and Walgreens to Provide COVID-19 Vaccine

    U.S. Dept. of Health and Human Services says Trump Administration Partners with CVS and Walgreens to Provide COVID-19 Vaccine to Protect Vulnerable Americans in Long-Term Care Facilities Nationwide | site |




    (October 16, 2020) - - Today, October 16, 2020, the U.S. Department of Health and Human Services (HHS) published the following information:

    To meet the Trump Administration's Operation Warp Speed (OWS) goals, the U.S. Department of Health and Human Services (HHS) and Department of Defense (DoD exit disclaimer icon) today announced agreements with CVS and Walgreens to provide and administer COVID-19 vaccines to residents of long-term care facilities (LTCF) nationwide with no out-of-pocket costs. Protecting especially vulnerable Americans has been a critical part of the Trump Administration’s work to combat COVID-19, and LTCF residents may be part of the prioritized groups for initial COVID-19 vaccination efforts until there are enough
    ...
    See more | Go to post

  • NIH begins Large Clinical Trial to Test Immune Modulators for Treatment of COVID-19

    National Institutes of Health begins Large Clinical Trial to Test Immune Modulators for Treatment of COVID-19 | site |





    (October 16, 2020) - - Today, October 16, 2020, The National Institutes of Health (NIH) published the following information:

    The National Institutes of Health has launched an adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19. Some COVID-19 patients experience an immune response in which the immune system unleashes excessive
    Colorized scanning electron micrograph of an apoptotic cell (green) heavily infected with SARS-COV-2 virus particles (yellow), isolated from a patient sample. Graphic courtesy NIAID
    amounts of proteins that trigger inflammation — called a “cytokine storm” — that can lead to acute respiratory distress syndrome,...
    See more | Go to post

  • CMS Survey Data Illustrates Impact of COVID-19 on Medicare Beneficiaries’ Daily Life and Experiences

    Centers for Medicare and Medicaid Services Survey Data Illustrates Impact of COVID-19 on Medicare Beneficiaries’ Daily Life and Experiences | site |



    (October 16, 2020) - - The Centers for Medicare and Medicaid Services published today, October 16, 2020, the following information: Today, the Centers for Medicare & Medicaid Services (CMS) released data showing that 21% of Medicare beneficiaries report forgoing non-coronavirus disease 2019 (COVID-19) care due to the pandemic, and nearly all - 98% - of beneficiaries have taken preventative measures to keep themselves safe from the virus. According to the survey, the most common type of forgone care because of the pandemic was dental care (43%), followed by regular check-up (36%), treatment for ongoing condition (36%), and diagnostic or medical screening test (32%). The most common reason cited for forgoing care was not wanting to risk being at a medical facility (45%). Regarding COVID-19 preventative health behavi...
    See more | Go to post

  • U.S. Food and Drug Administration Coronavirus - - - COVID-19 - - - Update: Daily Roundup October 13, 2020

    U.S. Food and Drug Administration Coronavirus - - - COVID-19 - - - Update: Daily Roundup October 13, 2020 | site |


    (October 13, 2020) - - Today, October 13, 2020, the U.S. Food and Drug Administration published the following information:

    The U.S. Food and Drug Administration (FDA) continued to take action in the ongoing response to the COVID-19 pandemic:
    ...
    See more | Go to post

  • BULLETIN—NIAID Stops Enrollment of Severely Ill COVID-19 Participants in Clinical Trial of Investigational Treatments

    BULLETIN—NIAID Stops Enrollment of Severely Ill COVID-19 Participants in Clinical Trial of Investigational Treatments | site |


    ACTT-3 Study Will Continue for Hospitalized Participants with Less Severe Illness


    Editor's note: Please note that this BULLETIN was published on September 29, 2020


    (September 29, 2020) - - On September 29, 2020, the National Institute of Allergy and Infectious Diseases published the following information:

    The Adaptive COVID-19 Treatment Trial 3 (ACTT-3), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will no longer enroll hospitalized participants with severe COVID-19 requiring high-flow oxygen, and will not begin to enroll patients requiring non-invasive or invasive mechanical ventilation. This action is being taken after an interim review of safety data by the study’s Data and Safety Monitoring Board (DSMB)
    ...
    See more | Go to post

  • NIH Study aims to Identify promising COVID-19 Treatments for larger Clinical Trials

    National Institutes of Health Study aims to Identify promising COVID-19 Treatments for larger Clinical Trials | site |



    (October 13, 2020) - - Today, the National Institutes of Health published the following information:

    The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today launched a study designed to determine whether certain approved therapies or investigational drugs in late-stage clinical development show




    This scanning electron microscope image shows SARS-CoV-2 (round gold objects) emerging from the surface of cells cultured in the lab. SARS-CoV-2, also known as 2019-nCoV, is the virus that causes COVID-19. The virus shown was isolated from a patient in the U.S.
    Graphic courtesy NIAID

    promise against COVID-19 and merit...
    See more | Go to post

  • Announcement says Johnson & Johnson Temporarily Pauses All Dosing in their Janssen COVID-19 Vaccine Candidate Clinical Trials

    Announcement says Johnson & Johnson Temporarily Pauses All Dosing in their Janssen COVID-19 Vaccine Candidate Clinical Trials | site |



    (October 12, 2020) - - Today, October 12, 2020, Johnson & Johnson published the following information:



    Johnson & Johnson Temporarily Pauses All Dosing in Our Janssen COVID-19 Vaccine Candidate Clinical Trials


    At Johnson & Johnson, there is no greater priority than the safety and well being of the people we serve every day around the world. We are committed to providing transparent updates throughout the clinical development process of our vaccine candidate, in compliance with regulatory standards and our own high ethical and scientific principles.

    We have temporarily paused further dosing in all our COVID-19 vaccine candidate clinical trials, including the Phase 3 ENSEMBLE trial, due to an unexplained illness in a study participant. Following our guidelines,
    ...
    See more | Go to post

  • U.S. Consumer Product Safety Commission says a COVID-19 Halloween Doesn’t Have to Be Scary

    U.S. Consumer Product Safety Commission Urges Families to Follow CDC Halloween Advice for Safe Celebrating; a COVID-19 Halloween Doesn’t Have to Be Scary | site |



    (October 6, 2020) - - Today, the U.S. Consumer Product Safety Commission (CPSC) published the following information:

    WASHINGTON, D.C. – The U.S. Consumer Product Safety Commission is urging families to follow Centers for Disease Control and Prevention (CDC) advice for Halloween this year. Among the key guidance: A Halloween mask is not an appropriate substitute for a protective cloth mask. CPSC joins with CDC in recommending that consumers wear a protective cloth mask of at least two layers of breathable fabric—not a costume mask. Protective masks should never be worn under a costume mask because it can become hard to breathe. If children or adults wear costumes this Halloween, be aware that costume fabrics and loose, billowy clothing (such as capes or gowns) can easily catch fire.
    ...
    See more | Go to post

  • American Federation of Teachers President Randi Weingarten on House COVID-19 Relief Package

    American Federation of Teachers President Randi Weingarten on House COVID-19 Relief Package | site |




    (October 2, 2020) - - Today, October 2, 2020, the American Federation of Teachers (AFT) published the following information: WASHINGTON—American Federation of Teachers President Randi Weingarten issued the following statement in response to the U.S. House of Representatives passing another COVID-19 relief package: “While we wish a speedy recovery for the president and first lady, and all those who have been affected in the White House and in Republican leadership by this newest COVID-19 outbreak, this makes abundantly clear that the pandemic is not over. The relief our communities need is real. While our country grapples with crisis after crisis, Speaker Nancy Pelosi and House Democrats have worked tirelessly to secure extended support for the people who need it: families worrying about how to pay their rent, parents worrying about how to keep their...
    See more | Go to post

  • U.S. Centers for Medicare and Medicaid Services Updates COVID-19 Testing Methodology for Nursing Homes

    U.S. Centers for Medicare and Medicaid Services Updates COVID-19 Testing Methodology for Nursing Homes | site |



    (September 29, 2020) - - The United States Centers for Medicare & Medicaid Services published today, September 29, 2020, the following information: Today, the Centers for Medicare & Medicaid Services (CMS) announced an update to the methodology the agency employs to determine the rate of coronavirus disease 2019 (COVID-19) positivity in counties across the country. Counties with 20 or fewer tests over 14 days will now move to “green” in the color-coded system of assessing COVID-19 community prevalence. Counties with both fewer than 500 tests and fewer than 2,000 tests per 100,000 residents, and greater than 10 percent positivity over 14 days – which would have been “red” under the previous methodology – will move to “yellow.” This information is critical to nursing homes, which are required to test their staff for COVID-19 at a freque
    ...
    See more | Go to post

  • National Institutes of Health to Assess and Expand COVID-19 Testing for Underserved Communities

    National Institutes of Health to Assess and Expand COVID-19 Testing for Underserved Communities | site |



    (September 30, 2020) - - Today, the National Institutes of Health (NIH) published the following information:

    The National Institutes of Health has awarded nearly $234 million to improve COVID-19 testing for underserved and vulnerable populations. A part of the Rapid Acceleration of Diagnostics (RADx) initiative, the RADx Underserved Populations (RADx-UP) program will support 32 institutions across the United States and will focus on populations disproportionately affected by the pandemic. These groups include African Americans, American Indians/Alaskan Natives, Latinos/Latinas, Native Hawaiians, older adults, pregnant women and those who are homeless or incarcerated. “It is critical that all Americans have access to rapid, accurate diagnostics for COVID-19, especially underserved and vulnerable populations who are bearing the brunt of th
    ...
    See more | Go to post

  • NIH expands Clinical Trials to Test Convalescent Plasma against COVID-19

    National Institutes of Health expands Clinical Trials to Test Convalescent Plasma against COVID-19 | site |


    Rigorous studies to build on earlier efforts to test the experimental treatment


    (September 22, 2020) - - Today the National Institutes of Health published the following information: Two randomized, placebo-controlled clinical trials funded by the National Institutes of Health (NIH) are expanding enrollment to further evaluate convalescent plasma as a treatment for patients hospitalized with COVID-19. Preliminary observational studies indicate that convalescent plasma may improve outcomes among severely ill and hospitalized patients with COVID-19. Prospective, well-controlled randomized trials are needed to generate sufficient data on whether convalescent plasma is effective and safe for the treatment of COVID-19. Convalescent plasma is blood plasma taken from people who have recovered from COVID-19. It contains antibodies that can recognize and
    ...
    See more | Go to post

  • NIH Funds Community Engagement Research Efforts in Areas Hardest Hit by COVID-19

    National Institutes of Health Funds Community Engagement Research Efforts in Areas Hardest Hit by COVID-19 | site |




    (September 16, 2020) - - Today, September 16, 2020, the U.S. Department of Health and Human Services (HHS) published the following information:

    The National Institutes of Health today announced a $12 million award for outreach and engagement efforts in ethnic and racial minority communities disproportionately affected by the COVID-19 pandemic. The award to RTI International, a non-profit research institution, will support teams in 11 states established as part of the NIH Community Engagement Alliance (CEAL) Against COVID-19 Disparities. These teams have received initial funding to immediately create CEAL programs, and RTI will serve as the Technical and Administrative Support and Coordination (TASC) center.


    The CEAL research teams will focus on COVID-19 awareness and education research, especially among African Americans,
    ...
    See more | Go to post

  • U.S. Food and Drug Administration Coronavirus COVID-19 Update - - Daily Roundup September 18, 2020

    U.S. Food and Drug Administration Coronavirus COVID-19 Update - - Daily Roundup September 18, 2020 | site |



    (September 18, 2020) - - Today, September 18, 2020, the U.S. Food and Drug Administration published the following information:

    The U.S. Food and Drug Administration (FDA) continued to take action in the ongoing response to the COVID-19 pandemic:
    • The FDA reissued the Emergency Use Authorization (EUA) for the Abbott ID Now COVID-19 test. The revisions to the previous EUA letter of authorization include a revised intended use to:
      • Indicate that testing is for specimens collected “from individuals who are suspected of COVID-19 by their health care provider within the first seven days of the onset of symptoms.”
      • Clarify that testing is authorized for laboratories certified under CLIA and meet the requirements to perform high, moderate, or waived complexity tests.
      • Clarify that testing facilities within the United States and its territories
    ...
    See more | Go to post

  • U.S. Food and Drug Administration Coronavirus COVID-19 Update - - Daily Roundup May 28, 2020

    Coronavirus (COVID-19) Update: Daily Roundup May 28, 2020| site |



    (May 28, 2020) - - Today (May 28, 2020), the U.S. Food and Drug Administration (FDA) published the following information:

    The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic:
    • The FDA issued an Emergency Use Authorization for the Stryker Sustainability Solutions (SSS) VHP N95 Respirator Decontamination System (RDS). This product uses vapor hydrogen peroxide (VHP) to decontaminate compatible N95 respirators that are, or potentially are, contaminated with SARS-CoV-2 or other pathogenic microorganisms for multiple-user reuse by healthcare personnel to prevent exposure to pathogenic biological airborne particulates when there are insufficient supplies of face-filtering respirators (FFRs) resulting from the Coronavirus Disease 2019 (COVID-19) pandemic. N95 respirators containing cellulose-based materials
    ...
    See more | Go to post

Menu

Collapse

Trending

Collapse

  • Staff Reporter 1
    HHS says Trump Administration Partners with CVS and Walgreens to Provide COVID-19 Vaccine
    by Staff Reporter 1
    U.S. Dept. of Health and Human Services says Trump Administration Partners with CVS and Walgreens to Provide COVID-19 Vaccine to Protect Vulnerable Americans in Long-Term Care Facilities Nationwide | site |




    (October 16, 2020) - - Today, October 16, 2020, the U.S. Department of Health and Human Services (HHS) published the following information:

    To meet the Trump Administration's Operation Warp Speed (OWS) goals, the U.S. Department of Health and Human Services (HHS) and Department of Defense (DoD exit disclaimer icon) today announced agreements with CVS and Walgreens to provide and administer COVID-19 vaccines to residents of long-term care facilities (LTCF) nationwide with no out-of-pocket costs. Protecting especially vulnerable Americans has been a critical part of the Trump Administration’s work to combat COVID-19, and LTCF residents may be part of the prioritized groups for initial COVID-19 vaccination efforts until there are enough
    ...
    10-20-2020, 04:28 AM
  • Staff Reporter 1
    NIH begins Large Clinical Trial to Test Immune Modulators for Treatment of COVID-19
    by Staff Reporter 1
    National Institutes of Health begins Large Clinical Trial to Test Immune Modulators for Treatment of COVID-19 | site |





    (October 16, 2020) - - Today, October 16, 2020, The National Institutes of Health (NIH) published the following information:

    The National Institutes of Health has launched an adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19. Some COVID-19 patients experience an immune response in which the immune system unleashes excessive
    Colorized scanning electron micrograph of an apoptotic cell (green) heavily infected with SARS-COV-2 virus particles (yellow), isolated from a patient sample. Graphic courtesy NIAID
    amounts of proteins that trigger inflammation — called a “cytokine storm” — that can lead to acute respiratory distress syndrome,...
    10-18-2020, 04:50 AM
  • Staff Reporter 1
    CMS Survey Data Illustrates Impact of COVID-19 on Medicare Beneficiaries’ Daily Life and Experiences
    by Staff Reporter 1
    Centers for Medicare and Medicaid Services Survey Data Illustrates Impact of COVID-19 on Medicare Beneficiaries’ Daily Life and Experiences | site |



    (October 16, 2020) - - The Centers for Medicare and Medicaid Services published today, October 16, 2020, the following information: Today, the Centers for Medicare & Medicaid Services (CMS) released data showing that 21% of Medicare beneficiaries report forgoing non-coronavirus disease 2019 (COVID-19) care due to the pandemic, and nearly all - 98% - of beneficiaries have taken preventative measures to keep themselves safe from the virus. According to the survey, the most common type of forgone care because of the pandemic was dental care (43%), followed by regular check-up (36%), treatment for ongoing condition (36%), and diagnostic or medical screening test (32%). The most common reason cited for forgoing care was not wanting to risk being at a medical facility (45%). Regarding COVID-19 preventative health behavi...
    10-18-2020, 04:21 AM
  • Staff Reporter 1
    U.S. Food and Drug Administration Coronavirus - - - COVID-19 - - - Update: Daily Roundup October 13, 2020
    by Staff Reporter 1
    U.S. Food and Drug Administration Coronavirus - - - COVID-19 - - - Update: Daily Roundup October 13, 2020 | site |


    (October 13, 2020) - - Today, October 13, 2020, the U.S. Food and Drug Administration published the following information:

    The U.S. Food and Drug Administration (FDA) continued to take action in the ongoing response to the COVID-19 pandemic:
    ...
    10-15-2020, 04:27 AM
  • Staff Reporter 1
    BULLETIN—NIAID Stops Enrollment of Severely Ill COVID-19 Participants in Clinical Trial of Investigational Treatments
    by Staff Reporter 1
    BULLETIN—NIAID Stops Enrollment of Severely Ill COVID-19 Participants in Clinical Trial of Investigational Treatments | site |


    ACTT-3 Study Will Continue for Hospitalized Participants with Less Severe Illness


    Editor's note: Please note that this BULLETIN was published on September 29, 2020


    (September 29, 2020) - - On September 29, 2020, the National Institute of Allergy and Infectious Diseases published the following information:

    The Adaptive COVID-19 Treatment Trial 3 (ACTT-3), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will no longer enroll hospitalized participants with severe COVID-19 requiring high-flow oxygen, and will not begin to enroll patients requiring non-invasive or invasive mechanical ventilation. This action is being taken after an interim review of safety data by the study’s Data and Safety Monitoring Board (DSMB)
    ...
    10-15-2020, 03:12 AM

Menu

Collapse

Menu

Collapse

Working...
X